Smith & Nephew is a medical devices company with strong growth profile (7.2/10), a perfect Piotroski F-Score of 9/9, and 140% free cash flow conversion, but faces a death cross price pattern, consecutive earnings misses, and a news sentiment modifier that has shifted the outlook toward selling for current holders.
Thesis pillars
- Strong Growth And Cash Conversion→Stable
- Consecutive Earnings Misses→Stable
- Death Cross Negative Momentum↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026· older than 90 days
Smith & Nephew SNATS, Inc. (SNN) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Sell if holding. Analyst target reached at $32.46 — A.R:R is negative (-0.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Consecutive earnings misses (2).
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced... Read more
Sell if holding. Analyst target reached at $32.46 — A.R:R is negative (-0.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Consecutive earnings misses (2). Chart setup: Death cross but MACD improving, RSI 74. Score 5.4/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 116d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated Nov 4, 2026Recent Developments — Smith & Nephew SNATS, Inc.
Latest news
- NEWS Smith & Nephew Ends Merger Talks with Johnson & Johnson's Orthopedics Unit and Cuts 2026 Outlook — fiscal.ai Nov 4, 2026 negative
- NEWS Smith+Nephew Q3 Revenue Rises 3.4% YoY To $1.551B; $250M Of $500M Buyback Completed; Confirms Johnson & Johnson Talks En — benzinga Nov 4, 2026 positive
- NEWS Smith & Nephew Implants Integrated into HipInsight System — fiscal.ai Nov 3, 2026 positive
- NEWS Citigroup Adjusts Price Target for Smith & Nephew — fiscal.ai Nov 3, 2026 neutral
- NEWS Smith & Nephew Reports Total Issued Share Capital — fiscal.ai Nov 2, 2026 neutral
Latest item Nov 4, 2026 · Generated 2026-11-05T11:49:11Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Negative sentiment — recent news tone and/or analyst downgrades drag the composite below neutral.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $32.46 — A.R:R is negative (-0.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Consecutive earnings misses (2). Chart setup: Death cross but MACD improving, RSI 74. Prior stop was $31.04. Score 5.4/10, moderate confidence.
Analyst target $28.12 reached (−13.4% from $32.46); no take-profit level is published. Prior stop was $31.04. Stop-loss: $31.04.
Analyst target reached - limited upside remaining; Consecutive earnings misses (2); Negative news sentiment (-1.00).
Smith & Nephew SNATS, Inc. trades at a P/E of 22.1 (forward 13.5). TrendMatrix value score: 6.5/10. Verdict: Sell.
24 analysts rate SNN, with a consensus score of 3.5/5. 5 analysts publish price targets averaging $32.
What does Smith & Nephew SNATS, Inc. do?Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and...
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.